Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Investigation of the VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation (VALUE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03639597
Recruitment Status : Completed
First Posted : August 21, 2018
Last Update Posted : April 24, 2019
Sponsor:
Information provided by (Responsible Party):
VytronUS, Inc.

Brief Summary:
The study is a single center, open-label, single arm, prospective pre-market study designed to assess the safety and efficacy of the VytronUS Ablation System (VAS) for the treatment of atrial fibrillation in patients with drug refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.

Condition or disease Intervention/treatment Phase
Paroxysmal Atrial Fibrillation Device: VytronUS Ablation System Not Applicable

Detailed Description:
Subjects with documented symptomatic, recurrent, PAF refractory to at least one beta blocker, calcium channel blocker or Class I or Class III anti-arrhythmic drug, who meet all inclusion/exclusion criteria and are deemed appropriate candidates for catheter ablation will undergo PV ablation with the VAS. Pre-procedural CT scan or MRI will be obtained to assess LA and PV anatomy and size. PV ablation will be performed utilizing the VAS (see procedure description below). Acute post-ablation confirmation of PV electrical isolation will be evaluated via standard mapping techniques.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Investigation of the VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation - The VALUE Study
Actual Study Start Date : January 18, 2016
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Study device
VytronUS Ablation System
Device: VytronUS Ablation System



Primary Outcome Measures :
  1. Primary Efficacy - Acute success and chronic freedom from AF, AFL and AT lasting longer than 30 seconds, freedom from new class I or II AAD [ Time Frame: 12 months ]
    Acute (or technical) procedural success defined as PVI documented by confirmed entrance block. Chronic success defined by freedom from symptomatic AF, AT and AFL lasting longer than 30 seconds, freedom from new class I or II AAD and no repeat ablation through 12 months of follow-up.

  2. Primary Safety - incidence of acute AEs occurring within 7 days of procedure and chronic adverse events [ Time Frame: 12 months ]
    Acute major AEs occurring within 7 days of procedure and chronic AEs defined as symptomatic PV stenosis >70% or symptomatic atrio-esophageal fistula diagnosed within 12 months.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 18 and 75 years
  2. History of symptomatic recurrent paroxysmal atrial fibrillation (PAF) in the prior year, defined by:

    a.Episodes of AF i.≥2 recurrent AF episodes of more than 30 seconds' duration that self-terminate and lasting no more than 7 continuous days or ii.Episodes of AF ≤ 48 hours duration terminated with electrical or pharmacologic cardioversion count as a paroxysmal atrial fibrillation episode b.At least one episode of paroxysmal atrial fibrillation (PAF) documented on 12-lead ECG, event monitor, or telemetry monitor in the prior year

  3. Paroxysmal atrial fibrillation refractory to at least one Beta Blocker, Calcium Channel Blocker, or Class I or Class III anti-arrhythmic drug (AAD).
  4. Subject is indicated for a pulmonary vein ablation according to society guidelines or investigational site practice.
  5. Subject is able and willing to give informed consent.
  6. Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full duration of the study.

Exclusion Criteria:

  1. Non-paroxysmal AF (e.g. persistent, long-standing persistent, or permanent AF)
  2. AF secondary to electrolyte imbalance, thyroid disease or reversible or non-cardiac cause.
  3. Prior LA ablation or surgery
  4. Women known to be pregnant or breastfeeding or of childbearing potential unless on satisfactory contraceptive routine
  5. NYHA Class III or IV congestive heart disease
  6. LVEF <40% measured by acceptable cardiac testing (eg. TTE, TEE)
  7. Anteroposterior LA diameter >5.5cm or <3.0cm by TTE
  8. Presence of intracardiac thrombus (including a known history of thrombus) within 30 days prior to the index ablation procedure
  9. Presence of pulmonary vein stent(s)
  10. Presence of pre-existing pulmonary narrowing or pulmonary vein stenosis
  11. Presence of a cardiac valve prosthesis
  12. Bleeding diathesis or contraindication to anticoagulation therapy
  13. Blood clotting abnormalities (genetic)
  14. MI, PCI, invasive cardiac procedure or surgery within 90 days prior to the index ablation procedure
  15. Previous CVA, TIA, or PE within 3 months prior to the index procedure
  16. Structural heart defect that, in the investigator's opinion, prevents catheter access or increases risk of ablation procedure
  17. Pacemaker, ICD, or CRT implantation within 6 months prior to the index ablation procedure
  18. Active systemic infection
  19. Subject contraindicated for both MRI and CT
  20. Life expectancy less than 360 days in physician's opinion
  21. Participation in a drug or device study
  22. Exclusion as per local laws -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03639597


Locations
Layout table for location information
Czechia
Na Homolce
Prague, Czechia
Sponsors and Collaborators
VytronUS, Inc.

Layout table for additonal information
Responsible Party: VytronUS, Inc.
ClinicalTrials.gov Identifier: NCT03639597     History of Changes
Other Study ID Numbers: 980-06114-00
First Posted: August 21, 2018    Key Record Dates
Last Update Posted: April 24, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by VytronUS, Inc.:
ablation
ultrasound
automation
catheter
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes